98%
921
2 minutes
20
Objectives: This study aimed to compare the efficacy of different interventions for myopia control in children, including 0.01% atropine (AP), orthokeratology (Ortho-k), and repeated low-level red-light therapy (RLRL), and their combinations by conducting a network meta-analysis.
Methods: We searched for randomised controlled trials (RCTs) in PubMed, Web of Science and Embase. The primary outcomes were the mean changes in the cycloplegic spherical equivalent (SE) and axial length (AL) at the 12-month follow-up. A Bayesian random-effects network meta-analysis was performed to estimate pooled weighted mean differences and 95% credible intervals.
Results: The analysis included 41 RCTs with 6434 eyes. Compared with the control group, all interventions were found to be effective at slowing myopia progression, combining direct and indirect evidence at the 12-month follow-up: RLRL therapy (AL -0.31 (0.39, 0.24), p<0.05; SE 0.76 (0.54, 0.98), p<0.05), 0.01% atropine (AL -0.13 (-0.20, 0.07), p<0.05; SE 0.25 (0.08, 0.42), p<0.05), Ortho-k therapy (AL -0.16 (-0.26, 0.06), p<0.05; SE 0.58 (0.05, 1.13), p<0.05) and 0.01% atropine+Ortho-k therapy (AL -0.27 (-0.38, 0.16), p<0.05; SE 0.76 (0.23, 1.31), p<0.05). The cumulative probability ranking suggested that RLRL therapy was the most effective intervention in slowing AL, followed by 0.01% atropine+Ortho-k, Ortho-k and 0.01% atropine.
Conclusions: This network meta-analysis provides evidence that RLRL, 0.01% atropine, Ortho-k and 0.01% atropine+Ortho-k are all effective in suppressing myopia progress. In terms of long-term treatment efficacy in slowing AL and SE procession, RLRL was the most effective intervention.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1136/bjo-2025-327366 | DOI Listing |
Sci Rep
August 2025
Department of Nursing, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, 322000, China.
This meta-analysis aimed to evaluate the effectiveness of repeated low-level red-light (RLRL) therapy compared to conventional myopia treatments to guide clinical application. A comprehensive literature search was conducted using PubMed, Embase, Web of Science, and Cochrane Library databases from their inception to December 2024. To quantify changes in axial length (AL), we computed weighted mean differences (WMDs) with 95% confidence intervals (CIs).
View Article and Find Full Text PDFTransl Pediatr
July 2025
Department of Pulmonary Disease, Wenjiang District Traditional Chinese Medicine Hospital, Chengdu, China.
Background: Childhood myopia has become a global public health problem and is growing rapidly in incidence, especially in East Asia. This study examined the prevention and control of myopia in children by systematically evaluating the interaction between genetic factors and visual behaviors to optimize prevention strategies.
Methods: Relevant articles were screened from PubMed and Web of Science.
Eye (Lond)
August 2025
School of Optometry and Vision Science, University of New South Wales, Sydney, NSW, Australia.
Myopia has become a leading cause of visual impairment globally, with a rapidly increasing prevalence among children, particularly in urbanised areas of East and Southeast Asia. High and pathologic myopia can lead to irreversible complications, including retinal detachment, glaucoma, and myopic maculopathy. This narrative review synthesises current and emerging strategies for myopia control as of 2025, integrating evidence from optical, pharmacological, behavioural, and surgical domains.
View Article and Find Full Text PDFIndian J Ophthalmol
August 2025
Department of Ophthalmology, Peking University People's Hospital, Beijing, China.
Objective: To assess the varying myopia control outcomes between morning (QM) and evening (QN) application of 0.01% atropine drops in conjunction with orthokeratology (ortho-K) therapy in myopic children.
Methods: A total of 163 right eyes of myopic children were included, receiving either morning or evening 0.
JAMA Ophthalmol
July 2025
Department of Preventative Ophthalmology, Shanghai Eye Diseases Prevention & Treatment Center/Shanghai Eye Hospital, National Clinical Research Center for Eye Diseases, Shanghai Engineering Research Center of Precise Diagnosis and Treatment of Eye Diseases, School of Medicine, Tongji University, Sha
Importance: Investigating the antimyopia efficacy and safety of orthokeratology and varying atropine doses in specific age groups could optimize personalized treatment choices.
Objective: To evaluate the efficacy and safety of orthokeratology, 0.04% atropine, and 0.